InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
4,567.18
(
-0.06%
)
US TECH 100
15,540.40
(
0.57%
)
Dow Jones
36,124.56
(
-0.22%
)
Brent Oil
77.25
(
0.26%
)
Bitcoin
43,855.83
(
-0.50%
)
RZLT
Rezolute Inc.
NASDAQ
Add Alert
Follow
9
RZLT
Rezolute Inc.
NASDAQ
Add Alert
Follow
9

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up
Live Updating
Older
Newer
profile icon
daleb2130 Free
09/04/20 7:39 PM
Post #146
Re: #145: @kanonman - more churn today...
Last Read
profile icon
kanonman Free
09/03/20 2:25 PM
Post #145
Last Read
profile icon
daleb2130 Free
09/02/20 9:56 PM
Post #143
Re: #141: @brianslate - With insider buying good sized quantities you would
Last Read
profile icon
brianslate Free
09/02/20 1:53 PM
Post #141
Last Read
profile icon
TrendTrade2016 Free
09/01/20 12:45 PM
Post #138
Last Read
profile icon
daleb2130 Free
09/01/20 12:40 PM
Post #137
Re: #136: @kanonman - needs to stay above .60 though
Last Read
profile icon
kanonman Free
09/01/20 12:39 PM
Post #136
Re: #135: @daleb2130 - A good start today
Last Read
profile icon
TrendTrade2016 Free
08/29/20 11:03 AM
Post #134
Last Read
profile icon
TrendTrade2016 Free
08/29/20 11:00 AM
Post #133
Re: #130: @kanonman - let it lose or let it LOOSE?
Last Read
profile icon
daleb2130 Free
08/28/20 10:31 PM
Post #132
Re: #131: @kanonman - and more today.... always a good sign
Last Read
profile icon
kanonman Free
08/28/20 9:46 PM
Post #131
Re: #126: @daleb2130 - Insiders keep buying. Always a good thing....... 5
Last Read
profile icon
daleb2130 Free
08/28/20 6:42 PM
Post #128
Re: #127: @TrendTrade2016 - RZLT enough is enough......time to let this lose!!
Last Read
profile icon
TrendTrade2016 Free
08/28/20 2:39 PM
Post #127
Last Read
profile icon
daleb2130 Free
08/25/20 5:01 PM
Post #126
Re: #125: @kanonman - it got close...back below .50 again...really wants to
Last Read
profile icon
kanonman Free
08/25/20 2:22 PM
Post #125
Re: #123: @TrendTrade2016 - HERE WE GO....60'S COMING IN FAST!!!
Last Read
profile icon
TrendTrade2016 Free
08/25/20 9:28 AM
Post #123
Re: #122: @TrendTrade2016 - GAPPA DAPPA DOO!! 53X54!!!ZOOOM!!!
Last Read
profile icon
TrendTrade2016 Free
08/25/20 9:15 AM
Post #122
Re: #121: @daleb2130 - Much More
Last Read
profile icon
SILVER HARVEST Free
08/24/20 5:26 PM
Post #119
Re: #117: @TrendTrade2016 - RZLT next week we see the 50's come
Last Read
profile icon
TrendTrade2016 Free
08/23/20 7:40 AM
Post #118
Last Read
profile icon
TrendTrade2016 Free
08/22/20 6:51 AM
Post #117
Last Read
profile icon
TrendTrade2016 Free
08/18/20 10:05 AM
Post #116
Last Read
profile icon
TrendTrade2016 Free
08/18/20 9:52 AM
Post #115
Re: #114: @TrendTrade2016 - RZLT heading to .54c then 57c and the
Last Read
profile icon
TrendTrade2016 Free
08/18/20 6:16 AM
Post #114
Last Read
profile icon
TrendTrade2016 Free
08/14/20 4:19 PM
Post #110
Last Read
profile icon
TrendTrade2016 Free
08/14/20 3:09 PM
Post #109
Last Read
profile icon
TrendTrade2016 Free
08/13/20 4:43 PM
Post #108
Last Read
profile icon
TrendTrade2016 Free
08/11/20 1:11 PM
Post #105
Last Read
profile icon
daleb2130 Free
08/11/20 12:34 PM
Post #104
Re: #103: @The Night Stalker - nice
Last Read
profile icon
daleb2130 Free
08/05/20 1:35 PM
Post #101
Last Read
profile icon
TrendTrade2016 Free
08/05/20 12:45 PM
Post #100
Last Read
profile icon
TrendTrade2016 Free
08/05/20 11:59 AM
Post #99
Last Read
profile icon
The Night Stalker Free
07/31/20 12:40 PM
Post #97
Re: #94: @The Night Stalker - beast
Last Read
profile icon
TrendTrade2016 Free
07/30/20 4:40 AM
Post #96
Last Read
profile icon
TrendTrade2016 Free
07/28/20 5:30 AM
Post #95
Re: #93: @beebread - Lmao at the 100k wall that was at
Last Read
Older
Newer

Rezolute Inc. (RZLT) RSS Feed

Followers
9
Posters
35
Posts (Today)
0
Posts (Total)
203
Created
01/20/13
Type
Free
Moderators
AntriaBioAntriaBio, Inc.
890 Santa Cruz Avenue
Menlo Park, CA 94025
P: (650) 223-5441
info@antriabio.com

Reverse Merger 

Jan 7, 2013 - AntriaBio, Inc., a biopharmaceutical company developing novel therapeutics for the diabetes market, is pleased to announce the acquisition of the significant assets of PR Pharmaceuticals, Inc. and its intention to become a publicly traded company through a merger.

"AB101 has the potential to be a clearly differentiated product that represents a significant advance in basal insulin delivery," said Nevan Elam, AntriaBio's President and CEO. "AB101 may offer significant advantages over basal insulin products sold by Sanofi-Aventis and Novo Nordisk, which together sell more than $7B annually."


AntriaBio's lead diabetes product candidate, AB101, is a once-a-week injectable basal insulin that is currently in preclinical development. AB101 is administered by subcutaneous injection and targets patients with type 1 and type 2 diabetes who require basal insulin for the control of hyperglycemia.

The formulation has been designed to release insulin slowly and uniformly over a period of approximately one week without an adverse initial burst of insulin. The release profile results in a low and sustained insulin level which supplements the effects of endogenous and exogenous insulin and complements the effects of orally administered hypoglycemic agents. AB101 has the potential to be a clearly differentiated product that represents a significant advance in basal insulin delivery.

AB101's long duration of action is the result of our ability to PEGylate insulin and then encapsulate it into poly-lactic, poly-glycolic (PLGA) microspheres. Currently available PEGylated biomolecules typically use large molecular weight PEG chains to decrease clearance and therefore reduce injection frequency. However, we use a very small molecular weight PEG for AB101 to modify the solubility of insulin and permit encapsulation of the drug into a biodegradable polymer.

After injection, the PEGylated insulin is slowly released at the injection site as the polymer microspheres are broken down by simple hydrolysis. Not only is our technology is unique, but also AB101 does not contain any new excipients and regulatory authorities have already approved numerous products using PEG or biodegradable polymers.

In addition to the proprietary technology for PEGylation of insulin and incorporation of the PEGylated insulin into biodegradable polymers, we have licensed proprietary microparticle manufacturing technology. The microsphere manufacturing process ensures production of a very tight particle size distribution with uniformly small microparticles. This is important to improve manufacturing efficiency and yields as well as to facilitate patient comfort by producing microspheres that can be injected through 25 gauge or smaller needles.

 

AntriaBio Appoints Two Industry Leaders to its Management Team
 
Menlo Park, CA - February 19th, 2013 - AntriaBio, Inc. is pleased to announce the appointment, on January 31, 2013, of two new members to its management team: Nevan Elam, AntriaBio's President and Chief Executive Officer and Sankaram Mantripragada, Ph.D, as AntriaBio's Chief Scientific Officer.
 
Nevan Elam has spent his entire career starting, managing and advising emerging growth companies in key areas of business including finance, marketing and clinical development. Prior to joining AntriaBio, Mr. Elam served as Chief Executive Officer of AeroSurgical Limited, a medical device company based in Europe. Prior to that, he directed the Pulmonary Business Unit of Nektar Therapeutics, which was sold to Novartis in 2008.
 
Mr. Elam also serves as a managing director of Konus Advisory Group, Inc. ("Konus"), a boutique healthcare consulting and investment firm that specializes in working with U.S. and European healthcare organizations on business opportunities in Asia, Latin America and the Middle East. Mr. Elam holds a J.D. from Harvard University and Bachelor's degree from Howard University.
 
Sankaram Mantripragada, Ph.D. brings to AntriaBio his strong understanding of the diabetes market and AntriaBio's unique platform technology. From June 2005 until October 2009, Dr. Mantripragada served as Vice President of R&D at PR Pharmaceuticals, Inc. ("PRP"). In January 2013, AntriaBio purchased substantially all of the PRP assets including significant technology, formulation, manufacturing, and intellectual property assets, which together form the basis of AntriaBio's drug development portfolio.
 
"Dr. Mantripragada's history with PRP's technology and formulation assets and his deep experience in diabetes products and markets make him a clear choice to lead our product development efforts," said Steve Howe, Chairman of AntriaBio. Mr. Howe served as Chairman and Chief Executive Officer of PRP from its formation in 1998 to 2010.
 
Dr. Mantripragada has been an advisor to companies specializing in diabetes, cell based therapies and cardiovascular diseases. He is listed as an inventor on more than 8 patents.
 
Prior to joining PRP, Dr. Mantripragada served as Director of R&D at Guidant Corporation, now part of Abbott Vascular. Prior to that, he served as Director of R&D and VP of Scientific Development at SkyePharma. Prior to that, he was an Assistant Professor of Biochemistry at the University of Virginia School of Medicine. Dr. Mantripragada obtained his Ph.D. in Molecular Biophysics from the Indian Institute of Science and completed a postdoctoral research program at the Max Planck Institute for Biophysical Chemistry in Germany.
 

 


chart
 
Most Liked Posts
(Last 30 Days)
Volume:
Day Range:
Last Trade Time:
Delayed by 15 minutes
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Detailed Quote
RZLT Latest News
More RZLT News
Most Liked Posts
(Last 30 Days)
New Post